Articles

INC Research holds a candle for Kendle

In a joint announcement today, INC Research, LLC, a global contract research organization (CRO) focused on therapeutics, and Kendle International Inc. announced the formation of a definitive merger agreement, under which INC Research will acquire Kendle.
Written byKelsey Kaustinen
| 2 min read

CINCINNATI and RALEIGH, N.C.—In a joint announcemnt today,INC Research, LLC, a global contract research organization (CRO) focused ontherapeutics, and Kendle International Inc. announced the formation of adefinitive merger agreement, under which INC Research will acquire Kendle. Theacquisition will be an all-cash transaction with a total equity value ofapproximately $232 million. INC Research, which is privately held by AvistaCapital Partners and Ontario Teachers' Pension Plan, will acquire all ofKendle's outstanding shares at $15.25 per share in cash, which represents a60.5 percent premium over Kendle's closing share price as of May 4 and a 51.3percent premium over the company's 30-trading average of closing prices.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.
3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.
3D illustration of a multicolored protein structure composed of folded ribbon-like strands against a blue and teal background with scattered spherical particles
Learn how advanced analytical methods support the characterization of antibody–C1q interactions and the qualification of analytical binding assays.